CSL LIMITED (CSL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CSL - CSL LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX20 | ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

CSL is a global biotechnology company that researches, develops, manufactures and markets products for the treatment of human diseases. With a market cap of over $138bn it is one of Australia's top three largest index weights. The former Commonwealth Serum Laboratory listed in June 1994 and has generated an average annual return of 28% since (up until mid-2020). CSL is the world's largest collector of plasma and the second largest producer of vaccines.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$294.31

03 Aug
2021

-0.040

OPEN

$292.38

-0.01%

HIGH

$295.00

418,485

LOW

$292.38

TARGET
$301.443 2.4% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . OPT . ANP .
FNARENA'S MARKET CONSENSUS FORECASTS
CSL: 1
Title FY21
Forecast		 FY22
Forecast
EPS (cps) 668.9 xxx
DPS (cps) 266.7 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 43.7 xxx
Dividend Yield 0.9% xxx
Div Pay Ratio(%) 39.9% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 1.38%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.94

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/03 - 134.14c (0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx691.1
DPS All xxxxxxxxxxxxxxx294.1
Sales/Revenue xxxxxxxxxxxxxxx13,575.3 M
Book Value Per Share xxxxxxxxxxxxxxx2,088.0
Net Operating Cash Flow xxxxxxxxxxxxxxx3,711.8 M
Net Profit Margin xxxxxxxxxxxxxxx23.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

21/07/2021

3

Hold

$280.00

-4.86%

Ord Minnett suspects the rapid increase of the delta strain of coronavirus in the US could be a cause for concern given the potential to disrupt recovery in plasma collections.

The broker remains hopeful the high rate of vaccination in the US will provide adequate protection and also points out, in its date-by-state analysis, CSL is not overly exposed to those states with low vaccination rates. Hold rating and $280 target maintained.

This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.

FORECAST
Ord Minnett forecasts a full year FY21 dividend of 285.07 cents and EPS of 639.40 cents.
Ord Minnett forecasts a full year FY22 dividend of 297.06 cents and EPS of 651.39 cents.

Credit Suisse

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CSL STOCK CHART

FNArena News on CSL

1
Weekly Ratings, Targets, Forecast Changes – 23-07-21

Jul 26 2021 - Weekly Reports
2
The Wrap: Oz Equities, Investors, Covid-Strategy, Housing

Jul 23 2021 - Australia
3
Rudi’s View: Is Risk-Off The Message?

Jul 15 2021 - Rudi's View
4
Rudi’s View: The Trend Is Still Our Friend

Jul 08 2021 - Rudi's View
5
Rudi’s View: Time For Quality To Shine

Jul 01 2021 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Flying High – Medicinal Marijuana In Australia

Jul 26 2021 - Australia
2
Wesfarmers On Drugs?

Jul 13 2021 - Australia
3
Is CSL’s Plasma Recovery Now Priced In?

Jun 23 2021 - Australia
4
CSL: Buy The Dip

Jun 22 2021 - Technicals
5
CSL To Retest Its High?

May 25 2021 - Technicals
6
Treasure Chest: CSL Plasma At Turning Point?

May 05 2021 - Treasure Chest
7
The War For Drugs

Apr 07 2021 - Weekly Reports
8
Rudi’s View: CSL, The Answers

Apr 01 2021 - Rudi's View
9
Is CSL Ready To Turn Around?

Mar 16 2021 - Australia
10
Opthea Targets Vision Improvement

Nov 18 2020 - Australia